BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results
August 5, 2015 6:44 AM EDTWedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $139.00 (from $130.00), following Q2 earnings. Q2 revenues of $250.5MM beat consensus ($218.2MM). GAAP-EPS of $(0.55) was below consensus of $(0.53) due to high Op-Ex.
Analyst Liana Moussatos commented, "Q2... More
Piper Jaffray Raises Price Target on BioMarin Pharma (BMRN) to $168 Following 2Q Results
August 4, 2015 8:41 AM EDTPiper Jaffray reiterated an Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $168.00 (from $163.00), following 2Q15 earnings results. Analyst Joshua Schimmer said that the results beat top and bottom line driven primarily by lumpy Naglazyme purchasing and reiterated... More
BioMarin (BMRN) PT Raised to $173 at Nomura; Increasingly Confident on Drisapersen
August 4, 2015 7:24 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $173.00 (from $163.00) following Q2 results, saying they are increasingly confident on Drisapersen.
Somaiya commented, "We are raising our BMRN TP to $173 from $163 following 2Q earnings which... More
